News and Comments

NORTHWEST BIOTHERAPEUTICS: AN EXAMPLE OF REFORM IN THE DRUG APPROVAL PROCESS.

  Tuesday, March 05, 2013

News has come from Northwest Biotherapeutics (NWBO) on its DCVax® personalized immune therapies for solid tumor cancers. The information is an announcement that Phase 1/2 DCVax-Direct clinical trial for all inoperable solid tumor cancers, which is planned to begin within approximately the next sixty days, will not be blinded. This means that the results will be seen as the trial proceeds. Knowing that an efficacy endpoint is tumor shrinkage or elimination), this trial is expected to yield meaningful ongoing results by the second half of 2013. More...

IDERA (IDRA): GOOD NEWS OFFSET SOMEWHAT BY SKEPTICISM NOT PESSIMISM

  Monday, March 04, 2013

Forgetting about Idera Pharmaceuticals (IDRA) seems to make its value sink, but failed to make it disappear. With a stock that sells at less than a three quarter of a dollar and a market of $20 million, lower than a new comer biotech having drugs still in preclinical lab testing, the firm was capable of drawing investors’ attention, riding new data about an attractive possibility of beating all existing approaches to treating psoriasis. The surprising data, which bring hopes in treating other autoimmune diseases, in addition to psoriasis were presented by James G. Krueger, M.D., PhD, of The Rockefeller University, at the Late-Breaking Research Symposium on March 2nd, 2013, during the American Academy of Dermatology Annual Meeting. More...


Recent Postings


Archive


Tags

KITE (KITE) Exelixis (EXEL) Benlysta (belimumab) PTC Therapeutics (PTCT) NOVOCURE (NVCR) VANDA (VNDA) Epizyme (EPZM) GUARDIAN HEALTH Endometrial Cancer Intercept (ICPT) Human Genome Sciences (HGSI) AstraZeneca (AZN) Ziofpharm (ZIOP) CompuGen (CGEN) Vertex (VRTX) REGULUS (RGLS) Biocryst (BCRX) RenenxBio (RGNX) Pluristem (PSTI) Alder Biopharmaceuticals (ALDR) Inovio (INO) BIOMARIN (BMRN) Valeant Pharmaceuticals International (VRX) OSI (OSIP) Sequenom (SQNM) Ionis (IONS) Rapamune IDERA (IDRA) Galena (GALE) Vitae Pharmaceuticals (VTAE) Elan (ELN) Sanofi-Aventis (SAN) Onyx (ONXX) KERYX (KERX) Tysabri Global Cell Therapeutics (GBT) ZALTRAP™ Theravance (THRX) Idenix (IDIX) Bellicum (BLCM) ARCA (ABIO) C4 Therapeutics Seattle Genetics (SGEN) ADVENTRIX (ANX) SERES THERAPEUTICS (MCRB) Ridaforolimus Prolor Biotech (PBTH) Sangamo (SGMO) AGOS (ARGS) LEXICON (LXRX) Human Longevity (HLI) SYNTA (SNTA) Ocular Therapeutix (OCUL) Sanofi (SNY) INNOVIVA (INVA) JOUNCE THERAPEUTICS (JNCE) ABBVIE (ABBV) Theravance Bio Pharma (TBPH) Zerenex Sarepta (SRPT) NEKTAR (NKTR)) Velcade (bortezomib) Mirati Therapeutics (MRTX) Anacor (ANAC) PORTOLA (PTLA) ISIS (ISIS) NEUROCRINE (NBIX) Sanofi (SNA) NANTKWEST (NK) JUNO (JUNO) Biogen Idec (BIIB) Xoma (XOMA) ARGOS (ARGS) Gilead (GILD) GlaxoSmithKline (GSK) Alnylam (ALNY) AERIE PHARMACEUTICALS Intermune (ITMN) Agenus (AGEN) Jazz Pharmaceuticals (JAZZ) Trastuzumab-DM1 Genentech Regeneron (REGN) Incyte (INCY) ImmunoGen (IMGN) Roche (RHHBY) ACADIA (ACAD) Abbott Laboratories (ABT) CRISPR Therapeutics (CRSP) Micromet (MITI) CEMPRA (CEMP) Telaprevir Amgen (AMGN) Roche (ROCHE) GlycoMimetics (GLYN) Akebia Therapeutics (AKAB) Intrexon (XON) OncoCyte (OCX) Spike Therapeutics (ONCE) Array Pharmaceuticals (ARRY) Bristol-Myers Squibb (BMY) Ariad (ARIA) Aimmune Therapeutics (AIMT) TOKAI (TKAOI) Herceptin SUNESIS PHARMACEUTICALS (SNSS) Revlimid (lenolidamide) Adaptimmune (ADAP) Agenus (AGEN Advaxis (ADXS) HALOZYME (HALO) Anadys (ANDS) Dynavax (DVAX) Prosensa (RNA) Merck (MRK) Illumina (ILMN) Cytokinetics (CYTK) Dendreon (DNDN) galapagos (GLPG) MODERNA Auspex (ASPX) Editas (EDIT) Multiple Myeloma